This assumption proved correct, as evident by the impressive anti-melanoma clinical responses achieved with anti-CTLA4/PD-1/PD-L1 antibodies (i.e. immune-checkpoint inhibitors or ICIs) [2, 3]. The gene discussed is CTLA4; the disease is melanoma.